Home › Calculator › INRLF Dividend Calculator 2026
INRLF Dividend DRIP Calculator 2026
57.97% YieldHealthcareValneva SE · OTC
Price: $3.45 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When INRLF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your INRLF snowball 📈
$10,000 in INRLF → $15.47M in 10 years · $950,514.46/month
About Valneva SE (INRLF) — Dividend Analysis 2026
Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization designed to actively protect against Japanese encephalitis. Another key product is DUKORAL, an oral vaccine intended to prevent diarrhea caused by Vibrio cholera and/or the heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also developed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva is advancing VLA15, a Lyme disease vaccine candidate that has successfully completed Phase II clinical trials. Furthermore, VLA1553, a candidate vaccine against the chikungunya virus, is currently undergoing Phase III clinical evaluation. Valneva distributes its products globally, with a market presence spanning the United States, Canada, Germany, Austria, the Nordic region, the United Kingdom, other European countries, and various international territories. The company has established significant strategic collaborations, including a partnership with Pfizer, Inc. to jointly develop and commercialize its Lyme disease vaccine. It also collaborates with Instituto Butantan on the development, manufacturing, and marketing of a single-dose chikungunya vaccine. Founded in 1998, Valneva SE is headquartered in Saint-Herblain, France.
Compare INRLF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full INRLF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open INRLF position with:
🌍 INRLF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold INRLF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 57.97% | 55.17% | $5,797 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 49.27% | 46.47% | $4,927 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 46.38% | 43.58% | $4,638 / yr |
| 🇬🇧 UK ISA | 0% | 57.97% | 55.17% | $5,797 / yr |
| 🇬🇧 UK Taxable | 8.75% | 52.90% | 50.10% | $5,290 / yr |
| 🇨🇦 TFSA | 0% | 57.97% | 55.17% | $5,797 / yr |
| 🇨🇦 CA Taxable | 25% | 43.48% | 40.68% | $4,348 / yr |
| 🇦🇺 Super (pension) | 15% | 49.27% | 46.47% | $4,927 / yr |
| 🇦🇺 AU Taxable | 30% | 40.58% | 37.78% | $4,058 / yr |
| 🇩🇪 DE Taxable | 26.375% | 42.68% | 39.88% | $4,268 / yr |
| 🇫🇷 FR Taxable | 30% | 40.58% | 37.78% | $4,058 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 INRLF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 INRLF Dividend Payment Schedule
INRLF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 INRLF vs Healthcare Benchmarks
How INRLF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for INRLF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ INRLF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the INRLF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Valneva SE (INRLF) is currently trading at $3.45, 89% below its 52-week high. The current dividend yield is 57.97% based on an annual payout of $2.00 per share.
INRLF (Valneva SE) — 57.97% Dividend Yield Analysis
Valneva SE (INRLF) is a healthcare stock currently trading at $3.45 with a dividend yield of 57.97%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (57.97%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest INRLF News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.